Daily Sepsis Research Analysis
Analyzed 58 papers and selected 3 impactful papers.
Summary
Three impactful sepsis papers stood out today: a mechanistic mouse study shows sleep interruption worsens sepsis via TLR2-dependent macrophage rewiring and is reversible with recovery sleep; a meta-analysis confirms bedside skin perfusion markers (mottling score, CRT, PPI) robustly predict mortality; and a large ICU cohort analysis associates presepsis statin use with reduced kidney events and mortality. Together, they span pathophysiology, bedside risk stratification, and pragmatic pharmacologic repurposing.
Research Themes
- Sleep-immune crosstalk and TLR2 signaling in sepsis pathophysiology
- Bedside microcirculatory assessment for mortality risk stratification
- Presepsis statin exposure and protection from kidney injury and death
Selected Articles
1. Sleep interruption aggravates sepsis by rewiring the macrophage immune response.
In mice, prior sleep interruption markedly worsened sepsis outcomes, increasing mortality and inflammatory cytokines, with effects largely dependent on TLR2 signaling in macrophages. Notably, 48 hours of recovery sleep reversed these effects, and RNA-seq revealed extensive transcriptional reprogramming of macrophages.
Impact: This mechanistic study links sleep disruption to worse sepsis via a defined TLR2-dependent pathway and demonstrates reversibility with recovery sleep, offering a modifiable target and testable behavioral intervention.
Clinical Implications: Promoting sleep continuity and minimizing nocturnal disruptions in ICU settings may attenuate harmful immune reprogramming in sepsis. These data prioritize trials of sleep-preserving bundles and exploration of TLR2-targeted modulation.
Key Findings
- Sleep interruption increased sepsis mortality (88% vs 57%; P=0.0045) and worsened disease scores in mice.
- Serum cytokines (IL-23 pre-sepsis; IL-6, TNF-α, MCP-1, IL-10 post-sepsis) and CD8+ T-cell activation were elevated.
- Macrophage cytokine amplification ex vivo was largely TLR2-dependent; TLR2 knockout abrogated the exacerbation.
- Forty-eight hours of recovery sleep reversed the detrimental effects, consistent with gene expression changes.
- RNA-seq identified 680 differentially expressed macrophage genes linked to pathogen defense and cytokine signaling.
Methodological Strengths
- Use of both sexes, survival outcomes, and multiplex cytokine profiling.
- Genetic validation with TLR2 knockout and transcriptomic (RNA-seq) analyses; demonstration of reversibility with recovery sleep.
Limitations
- Preclinical mouse model limits direct generalizability to human ICU settings.
- Sleep interruption paradigm may not fully recapitulate complex ICU sleep disturbances or comorbidities.
Future Directions: Prospective ICU trials testing multimodal sleep-preserving bundles and mechanistic studies of TLR2-pathway modulation in human myeloid cells during sepsis.
Sepsis is the leading cause of death in hospitals and is very common in intensive care units (ICUs). Sleep is frequently interrupted in the hospital setting, especially within the ICU. Patients who sleep poorly have worse outcomes, such as increased mortality and longer hospital stays; however, the molecular basis remains poorly understood. In this study, we utilized a mouse model to investigate the impact of sleep interruption on subsequent sepsis. We found that sleep interruption aggravated sepsis, as evidenced by higher mortality rates (88% in mice with interrupted sleep vs 57% in mice with normal sleep; P = 0.0045) and worse disease scores. This effect occurred in both females and males. Sleep interruption increased circulating T cells and CD8+ T-cell activation during sepsis. Sleep interruption also increased the levels of serum cytokines (including IL-23 before sepsis was induced, and IL-6, TNF-α, MCP-1, and IL-10 after sepsis), and amplified macrophage cytokine production ex vivo. These ex vivo effects were largely dependent on Toll-like receptor 2 (TLR2), and sleep interruption no longer exacerbated sepsis in TLR2 knockout mice. Interestingly, the effects of sleep interruption on sepsis were reversed by 48 hours of recovery sleep, consistent with a mechanism involving altered gene expression rather than epigenetic changes. RNA sequencing identified 680 genes that were significantly up- or downregulated in macrophages from animals subject to sleep interruption, including multiple genes related to pathogen defense and cytokine signaling. Our study confirms that good sleep is essential to maximize sepsis survival and provides insight into the molecular basis whereby poor sleep alters immune function.
2. Meta-analysis of the prognostic value of skin perfusion parameters in sepsis patients: Evidence integration based on the Mottling Score, capillary refill time, and peripheral perfusion index.
Across 22 studies (n=2,727), higher mottling score, prolonged CRT, and low PPI were each strongly associated with increased 14–28 day and in-hospital mortality in sepsis. PPI showed the largest association with 28-day mortality (OR≈5.05). Sensitivity analyses suggested robust findings without significant publication bias.
Impact: Synthesizes heterogeneous bedside microcirculatory markers into actionable mortality risk predictors, supporting integration into triage and resuscitation decisions.
Clinical Implications: Routine assessment of CRT, mottling score, and PPI can enhance early risk stratification and guide individualized resuscitation targets in sepsis, especially where advanced hemodynamic monitoring is limited.
Key Findings
- Mottling score associated with 28-day mortality (OR 2.27; 95% CI 1.79–2.87) and 14-day mortality (OR 1.96; 95% CI 1.32–2.91).
- Prolonged CRT associated with 28-day mortality (OR 3.29; 95% CI 2.08–5.21) and in-hospital mortality (OR 2.46; 95% CI 1.18–5.12).
- Low PPI associated with 28-day mortality (OR 5.05; 95% CI 3.65–6.98) and in-hospital mortality (OR 4.56; 95% CI 3.32–6.26).
- Sensitivity analyses supported robustness; no significant publication bias detected.
Methodological Strengths
- Comprehensive multi-database search with dual independent screening and NOS risk-of-bias assessment.
- Consistent results across sensitivity analyses and multiple bedside indices.
Limitations
- Predominantly observational cohorts; residual confounding cannot be excluded.
- Heterogeneity in measurement protocols and threshold definitions across studies.
Future Directions: Prospective, standardized protocols for CRT/PPI/mottling with predefined thresholds and interventional trials testing perfusion-targeted resuscitation.
BACKGROUND: Despite advances in intensive care, sepsis and septic shock still have high morbidity and mortality. Microcirculatory disturbance is a key issue in sepsis, leading to hypoperfusion, hypoxia, and organ failure. The skin is a sensitive indicator of microcirculatory changes and often shows early systemic changes. Recently, bedside skin perfusion indicators such as the Mottling score (MS), Capillary Refill Time (CRT), and Peripheral Perfusion Index (PPI) have become common in practice. However, their value in predicting outcomes lacks strong evidence. METHODS: A systematic search was conducted across databases, including PubMed, Web of Science, Cochrane Library, EBSCO, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP, with a search period spanning from the inception of the databases to January 2026. Cohort studies or case-control studies investigating the correlation between skin perfusion parameters and the prognosis of sepsis patients (primary outcomes: 28-day mortality, 14-day mortality, and in-hospital mortality) were included. Two researchers independently performed literature screening, data extraction, and assessment of the Newcastle-Ottawa Scale (NOS) bias risk. A meta-analysis was performed using RevMan 5.4.1 software. RESULTS: This study included a total of 22 articles, encompassing 2,727 study subjects. The meta-analysis results demonstrated that: (1) Mottling Score (MS), was significantly associated with 28-day mortality (Odds Ratio OR=2.27, 95% Confidence Interval CI: 1.79, 2.87, P<0.001) and 14-day mortality (OR=1.96, 95% CI: 1.32, 2.91, P<0.001); (2) Prolonged Capillary Refill Time (CRT) duration was significantly associated with 28-day mortality (OR=3.29, 95% CI: 2.08, 5.21, P<0.001) and in-hospital mortality (OR=2.46, 95% CI: 1.18, 5.12, P<0.001); (3) Reduced Peripheral Perfusion Index (PPI) was significantly associated with 28-day mortality (OR=5.05, 95% CI: 3.65, 6.98, P<0.001) and in-hospital mortality (OR=4.56, 95% CI: 3.32, 6.26, P<0.001). Sensitivity analysis confirmed robust results with no significant publication bias. CONCLUSION: The MS, CRT, and PPI, as bedside and non-invasive skin perfusion parameters, demonstrate significant predictive value for mortality risk in sepsis patients. Integrating these indicators facilitates early clinical identification of high-risk patients, guiding risk stratification and resuscitation therapy. Future large-sample prospective studies are required to further standardize their assessment protocols and intervention thresholds.
3. Association of Presepsis Statin Prescription With Kidney and Mortality Outcomes: Cause-Specific, Overlap-Weighted Analyses.
In a 30,765-patient ICU cohort meeting Sepsis-3, presepsis statin prescription was associated with lower risks of kidney outcomes and mortality using overlap weighting and cause-specific Cox models. Protective associations were broadly consistent across subgroups.
Impact: Provides robust real-world evidence that common, inexpensive statins may confer renal and survival benefits in sepsis, justifying prospective trials and potential risk-based continuation strategies.
Clinical Implications: For patients already on statins at sepsis onset, continuation may be reasonable absent contraindications; findings support prioritizing RCTs to define causality, drug class effects, and dosing.
Key Findings
- Presepsis statin prescription associated with reduced kidney outcome risk (HR 0.83; 95% CI 0.80–0.87).
- Lower mortality without prior kidney outcome (HR 0.56; 95% CI 0.51–0.63) and overall mortality (HR 0.78; 95% CI 0.71–0.84).
- Subgroup signals suggested greater kidney protection in patients <65 years, without CKD, and with hypertension; survival benefits were broadly consistent.
Methodological Strengths
- Large sample size with overlap weighting to balance covariates and cause-specific Cox modeling.
- Predefined composite kidney outcome and consistent subgroup analyses.
Limitations
- Single database, retrospective design with potential residual confounding and indication bias.
- Incomplete capture of sepsis severity measures; exposure defined by prescription within 24 hours may misclassify adherence.
Future Directions: Randomized trials to test continuation/initiation strategies, head-to-head statin class comparisons, and dose–response in sepsis with kidney endpoints.
RATIONALE & OBJECTIVE: Sepsis, complicated by kidney injury, poses a mortality risk in intensive care unit patients. Although statins are thought to offer protective effects against kidney injury through anti-inflammatory mechanisms, evidence remains inconclusive. This study aimed to evaluate whether statin prescription before sepsis onset affects the risks of kidney injury and mortality. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Adult intensive care unit patients who met Sepsis-3 criteria in Medical Information Mart for Intensive Care-IV. EXPOSURE: Statin prescription within the 24 hours preceding sepsis onset. OUTCOMES: The primary outcome was the prespecified kidney outcome (need for kidney replacement therapy or a reduction in estimated glomerular filtration rate of ≥50%). Secondary outcomes were mortality without the kidney outcome (cause-specific) and overall mortality. ANALYTICAL APPROACH: We used overlap weighting to balance baseline characteristics. Cause-specific Cox models estimated associations for the kidney outcome and mortality without the kidney outcome; a weighted Cox model estimated associations for overall mortality. RESULTS: The final cohort included 30,765 patients with sepsis, with 19.3% exposed to statins. Statin prescription was associated with a reduced risk of kidney outcome (HR, 0.83; 95% CI, 0.80-0.87), mortality without kidney outcome (HR, 0.56; 95% CI, 0.51-0.63), and overall mortality (HR, 0.78; 95% CI, 0.71-0.84). Subgroup analyses were broadly consistent across prespecified strata. For the kidney outcome, interaction testing suggested greater risk reduction among patients aged <65 years, those without chronic kidney disease, and those with hypertension. For death without prior kidney outcome and for overall mortality, protective associations were consistent across subgroups, with a larger effect among patients with prior myocardial infarction. Overall, statin prescription was consistently associated with lower risks of kidney outcome and mortality. LIMITATIONS: Single-database retrospective design and incomplete capture of sepsis severity measures. CONCLUSIONS: Presepsis statin prescription was associated with lower risks of kidney outcome and mortality, indicating potential clinical benefits in patients with sepsis. Sepsis is a severe infection that can threaten life and damage organs. Statins are medicines best known for lowering cholesterol, but they may also reduce inflammation and stabilize blood vessels. We studied adults in intensive care who met modern (Sepsis-3) criteria for sepsis and compared patients who were prescribed a statin within 24 hours before sepsis onset with those who were not. People who were taking statins before sepsis started had lower risks of kidney function decline and death. The association seemed stronger for survival than for kidney outcomes. These findings suggest that statins may offer clinical benefits for patients with sepsis and motivate future work to determine which statin types and doses are most helpful.